FERM domain-containing unconventional myosin VIIA interacts with integrin β5 subunit and regulates αvβ5-mediated cell adhesion and migration  by Liu, Yuqing et al.
FEBS Letters 588 (2014) 2859–2866journal homepage: www.FEBSLetters .orgFERM domain-containing unconventional myosin VIIA interacts
with integrin b5 subunit and regulates avb5-mediated
cell adhesion and migrationhttp://dx.doi.org/10.1016/j.febslet.2014.06.049
0014-5793/ 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
⇑ Corresponding author at: Laboratory of Molecular Cell Biology and Tumor
Biology, Department of Histology and Embryology, School of Basic Medical Sciences,
Peking University Health Science Center, #38 Xue Yuan Road, Beijing 100191,
China.
E-mail address: Hongquan.Zhang@bjmu.edu.cn (H. Zhang).Yuqing Liu, Lizhao Guan, Jun Zhan, Danyu Lu, Junhu Wan, Hongquan Zhang ⇑
Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Health Science Center, Beijing 100191, China
State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing 100191, China
Laboratory of Molecular Cell Biology and Tumor Biology, Department of Anatomy, Histology and Embryology, Peking University Health Science Center, Beijing 100191, Chinaa r t i c l e i n f o
Article history:
Received 16 April 2014
Revised 16 June 2014
Accepted 17 June 2014
Available online 2 July 2014
Edited by Dietmar J. Manstein
Keywords:
Myosin VIIA
Integrin b5 subunit
Cell adhesion
Cell migration
Hereditary deafnessa b s t r a c t
Unconventional myosin VIIA (Myo7a) has been known to associate with hereditary deafness. Here
we present a novel function of Myo7a by identifying that Myo7a directly interacts with integrin
b5 subunit and regulates cell adhesion and motility in an integrin-dependent manner. We found
that Myo7a bound to the cytoplasmic tail of integrin b5. Further, we pinpointed an integrin-binding
domain at F3 of the ﬁrst FERM domain and F1 of the second FERM domain. Functionally, Myo7a-
induced cell adhesion and migration were mediated by integrin avb5. These ﬁndings indicated that
Myo7a interacts with integrin b5 and selectively promotes integrin avb5-mediated cell migration.
Structured summary of protein interactions:
integrin B5 physically interacts with Myo7a by pull down (1, 2, 3, 4, 5, 6)
Myo7a binds to integrin B5 by pull down (1, 2)
integrinB5 physically interacts with Myo7a by anti bait coip (1, 2, 3)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Integrins, as heterodimeric transmembrane receptors, mediate
interactions between cells and extracellular matrix (ECM) and
are involved in cell adhesion and migration [1]. Integrins are com-
posed of a and b subunits, 18 a and 8 b subunits form 24 distinct
integrin hetrodimers [2]. Integrin a and b subunit both contain a
large N-terminal extracellular domain, a single transmembrane
domain and a short C-terminal cytoplasmic tail. Integrins regulate
the binding afﬁnity with ECM through an inside-out signaling and
control cell migration via an outside-in signaling [1]. Unconven-
tional myosins are a superfamily of actin-based motor proteins
implicated in diverse cellular processes, including cytokinesis,
pseudopod extension, vesicle transport and phagocytosis [3,4]. As
a member of them, myosin VIIA (Myo7a) is mainly expressed inthe stereocilia in the inner ear and is required for the maintenance
of the structure of stereocilia. Increasing evidence has suggested
that Myo7a associate with hereditary hearing loss. Mutations in
MYO7A cause syndromic (USH1B) [5] and non-syndromic (DFNB2
and DFNA11) [6,7] deafness in humans, and are also responsible
for the phenotype of shaker-1 mice [8].
Structurally, unconventional myosins are composed of a con-
served motor head, a neck region and a variable tail. It is known
that the tails differ extremely in length and domain composition
among myosin family members, which determines the cellular
localization and function of the myosin. Notably, the tail of Myo7a
contains several domains, including two FERM domains. Each
FERM domain typically is composed of F1, F2 and F3 lobes, which
interact directly or indirectly with multiple integral membrane
proteins, link the cytoskeleton to the plasma membrane, and thus
participate in a variety of cellular functions, such as the regulation
of cell extension and polarity, cell migration, etc. [9,10]. Talin, a
FERM-containing protein, has been reported to bind to integrin b
subunit tail through its F2 and F3 subdomains and therefore acti-
vates integrins [11]. Kindlin-2, another FERM domain-containing
protein that activates integrins, also interacts with integrin b
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found that unconventional Myo10 interacts with integrin b cyto-
plasmic domain and regulates integrin transport within ﬁlopodia
via the lobes F2 and F3 of its FERM domain [13]. Thus, we proposed
a hypothesis that Myo7a may also interact with integrin cytoplas-
mic domain and plays a role in integrin-mediated cellular func-
tions such as cell adhesion and migration. Here, we identiﬁed
that Myo7a directly interacted with integrin b5 cytoplasmic
domain. Furthermore, the roles of Myo7a in integrin b5-mediated
cellular functions were examined in non-stereocilia cells. Taken
together, we present the ﬁrst report that Myo7a regulates cell
adhesion and migration in non-stereocilia cells by association with
integrin avb5.
2. Materials and methods
2.1. Cell lines
African green monkey kidney COS-7 cells, human embryonic
kidney 293T cells and human breast cancer MCF-7 cells were
cultured in DMEM medium (Invitrogen, Carlsbad, CA) and mouse
melanoma B16 cells were cultured in RPMI 1640 medium
(Invitrogen, Carlsbad, CA). Both culture mediums were supplemen-
ted with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA),
100 IU/ml of penicillin and 100 lg/ml of streptomycin respectively.
The cells were cultured at 37 C with 5% CO2 in a humidiﬁed
incubator.
2.2. cDNA expression vectors
GST-integrin b1, GST-integrin b3 and GST-integrin b5 cytoplas-
mic domain fusion protein expression vectors were kindly pro-
vided by Dr. Staffan Strömblad (Karolinska Institutet, Sweden)
[14]. A full-length mouse GFP-Myo7a plasmid (Accession No.
AY821853) was kindly provided by Dr. Thomas B. Friedman
(National Institute of Health, USA) [15]. A full-length Myo7a ORF
was excised from the GFP-Myo7a plasmid with EcoRI/SalI restric-
tion enzymes, ﬁlled in 50-protruding ends using DNA polymerase
I large (Klenow) fragment (Promega, Madison, WI, USA), and
cloned in-frame into the EcoRI/EcoRV sites of a mutant
p3  Flag-CMV 10 vector with a G inserted ahead of EcoRI site to
generate plasmid Flag-Myo7a. The Flag-tagged, GFP-tagged and
MBP-tagged Myo7a fragments were all PCR ampliﬁed from
GFP-Myo7a plasmid, and cloned in-frame into the mutant
p3  Flag-CMV 10 vector, pEGFP-C2 vector and pMal-C2 vector
respectively. All the primers used were listed in Supplementary
Table 1.
2.3. Western blot assays
Cell lysates were prepared using PBSTDS lysis buffer (0.01 M
PBS, 1% Triton X-100, 5 g/L Sodium deoxycholate, 0.1% SDS and
1 mM EDTA) containing cocktail protease inhibitor (Boehringer
Mannheim, Mannheim, Germany). Proteins were denatured at
95 C for 5 min and then separated by SDS–PAGE. Separated pro-
teins were transferred to PVDF membranes (Millipore, Billerica,
MA) following blocked by 5% milk in TBS-Tween-20 buffer for 1 h
and incubated with anti-Myo7a antibody (ab3481, Abcam,
Cambridge, MA), anti-Flag (F3165, Sigma–Aldrich, St. Louis, MO),
anti-integrin b5 (D24A5, Cell Signaling Technology, Danvers, MA),
anti-GFP antibody (MAB 1083, Millipore, Darmstadt, Germany) or
anti-b-actin (TA-09, Zhongshan golden bridge, Beijing, China)
overnight at 4 C. After washing for 3 times in TBS buffer, the
membranes were incubated with HRP-conjugated secondary
antibody for 1 h at room temperature. The signal was detected
using a chemiluminescence detection kit (Pierce, Rockford, IL).2.4. Puriﬁcation of fusion proteins and GST pull-down assays
GST, GST-integrin b1, GST-integrin b3 or GST-integrin b5 and
MBP, MBP-Myo7a FERM-1or MBP-Myo7a FERM-2 were expressed
in Escherichia coli BL21 (Tiangen Biotechnology, Beijing, China),
and puriﬁed with Glutathione Sepharose 4B beads (Pharmacia
Medtech, Piscataway, NJ) or MBP-Afﬁnity Matrix (Amylose Resin,
New England Biolabs). GST/MBP pull-down assays were performed
as described previously [16]. Brieﬂy, GST or GST-fusion protein was
incubated with Glutathione Sepharose 4B beads by rocking at 4 C
for 4 h, and then the beads were washed three times with TEN
buffer (20 mM Tris–HCl, pH 7.4, 0.1 mM EDTA, and 100 mM NaCl)
followed by incubating with pre-cleared lysates overnight at 4 C.
And the beads were dissolved into 2  SDS loading buffer after
centrifugation, and boiled 5 min at 100 C.
2.5. Co-immunoprecipitation (Co-IP)
A Co-IP assay was performed as described previously [16].
Brieﬂy, B16 cells were transfected with pFlag-Myo7a tail by
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Total cell lysates
were extracted using RIPA buffer (1  PBS, pH 7.4, 0.5% sodium
deoxycholate, 1% Triton X-100, 0.1% SDS) with cocktail protease
inhibitors. Approximately 500 lg of pre-cleared lysates were
immunoprecipitated by speciﬁc antibodies with constant rotation
overnight at 4 C. Protein A agarose beads were then added and
incubated for another 2 h. Then the beads were washed three times
using the lysis buffer. 2  SDS loading buffer was added to the
mixture, and boiled for 5 min at 95 C.
2.6. RNA interference
Two Myo7a siRNAs were designed based on the mouse Myo7a
cDNA sequence: CAGAGTCATTCTCCTCCAGAA and CCAGGTGTTCTT
CATGAAGAA. An irrelevant siRNA sequence CGAGUGGUCUAGUUG
AGAA was used as control. To examine the silencing efﬁciency of
Myo7a siRNA, B16 cells were transfected with synthetic siRNA or
control siRNA (QIAGEN, Hilden, Germany) at a ﬁnal concentration
of 100 nM using Lipofectamine RNAiMAX (Invitrogen, Carlsbad,
CA) as described by the manufacturer.
2.7. Generation of mutations
Point mutants were generated using the QuickChange XL Site-
Directed Mutagenesis Kit (Stratagene). Myo7a siRNA-resistant
mutant is a siRNA-2-resistant Myo7a G5826C/C5829T mutant.
2.8. Cell adhesion and spreading assays
For cell adhesion, non-treated 48-well plates (Corning Costar
Corp., Tewksbury, MA) were coated with 100 ll of 6 lg/ml Vitro-
nectin (VN) (Merck KGaA, Darmstadt, Germany), Fibronectin (FN)
(Merck KGaA, Darmstadt, Germany) or type I collagen (Sigma–
Aldrich, St. Louis, MO) overnight at 4 C. 1% Heat-denatured BSA
was applied to block non-speciﬁc adhesion at 37 C for 1 h.
300 ll of cell suspension were seeded into the wells in triplicate
at 5  104 cells/well in cell adhesion buffer (RPMI 1640, 2 mM
CaCl2, 1 mM MgCl2, 0.2 mM MnCl2 and 0.5% BSA) and allowed to
attach for 30 min at 37 C. After careful washing with adhesion
buffer to remove non-bound cells, WST-1 (Beyotime Institute of
Biotechnology, Shanghai, China), a water-soluble tetrazolium salt
for MTT Assays, was used to quantify the number of cells attached.
The morphology of cells during the spreading was analyzed at
30-min time points. Adherent cells were treated with 4% formalde-
hyde for 15 min and typically 15 microscopic ﬁelds were randomly
chosen to be photographed and analyzed.
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length, B16 cells were co-transfected with Myo7a siRNA and
Flag-Myo7a WT or Flag-Myo7a siRNA resistant mutant, and
replated on VN 48 h after transfection. The quantiﬁcation of ﬁlopo-
dia length was performed as described previously. In brief, cells
were selected randomly and all eligible ﬁlopodia of selected cells
were measured with Slidebook 6. About 100 cells were measured
for each condition in each experiment, and displayed data are
representative of three experiments. Statistical evaluation for ﬁlo-
podia length was performed with software GraphPad Prism 5.
2.9. Transwell migration assays
Haptotactic cell migration assays were performed using Trans-
well chambers (Corning Costar Corp., Tewksbury, MA) with 8.0 lm
pore size. The lower surface of Transwell membranes were coated
with FN (10 lg/ml) at 37 C for 1 h. 48 h After transfection 5  104
cells were seeded on the top of the Transwell membranes in the
presence or absence of anti-integrin avb5 mAb P1F6 (Chemi-Con,
Rosemont, Illinois) followed by 6 h incubation at 37 C in RPMI
1640 with 2 mM CaCl2, 1 mM MgCl2, 0.2 mM MnCl2 and 0.5%
BSA. The Transwell membrane was then ﬁxed withFig. 1. Myo7a interacts with the integrin b5 subunit. (A) Sectioned bar diagram depicts th
GST-b3 and GST-b5 cytoplasmic domain fusion protein were used to pull down Flag-Myo
lysate containing Flag-Myo7a. (C) GST-b5 cytoplasmic domain fusion protein was used t
interacted directly with integrin b5 in a GST pull-down assay. (E) Myo7a tail domain asso
Myo7a tail. 48 h after transfection, cell lysates were immunoprecipitated with an anti-in
anti-Flag antibody and an anti-integrin b5. 10 lg cell lysates containing Flag-Myo7a tail w
in B16 cells was analyzed in a Co-IP assay.4% formaldehyde for 15 min and stained by crystal violet. Typically
15 microscopic ﬁelds were randomly chosen for analyses.
2.10. Statistical analysis
All experiments were repeated for three times, and data were
presented as means ± SD. Comparisons between two groups were
made using unpaired t-test. Differences among more than two
groups were compared using one-way ANOVA. P value less than
0.05 was considered as statistically signiﬁcant.
3. Results
3.1. Myo7a directly interacts with integrin b5 cytoplasmic domain
Myo7a contains FERM domains in its tail (Fig. 1A), which has
been known to determine the cellular localization and function
in a variety of integrin-interacting proteins, and that gives us a hint
about how Myo7a exerts its biological functions. To examine this
hypothesis, puriﬁed Glutathione S-transferase (GST)-integrin b1,
integrin b3 or integrin b5 cytoplasmic domain fusion proteins were
incubated with total lysates from COS-7 cells transfected withe domain structure of Myo7a full, Myo7a motor and Myo7a tail. (B) Puriﬁed GST-b1,
7a expressed in COS-7 cells, with GST alone as control. The left lane shows the input
o pull down endogenous Myo7a in B16 cells. (D) Myo7a tail domain but not motor
ciates with integrin b5 in Co-IP assays. B16 cells were transfected with Flag-tagged
tegrin b5 antibody and an anti-Flag antibody followed by immunoblotting using an
ere loaded as input. (F) The interaction between endogenous Myo7a and integrin b5
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action between Myo7a and GST-b5 cytoplasmic domain (Fig. 1B).
In this study, we identiﬁed that Myo7a was highly expressed in
B16 cells (Supplementary Fig. 1). Herein, endogenous Myo7a in
mouse melanoma B16 cells was pulled down by GST-fused integrin
b5 cytoplasmic domain (Fig. 1C). To map the binding regions
between Myo7a and integrin b5, Myo7a was roughly divided intoFig. 2. Mapping of the integrin b5-binding region in the Myo7a tail. (A) Schematic illustr
Myo7a. (B) Various regions of the Myo7a tail were cloned into vector pEGFP and then we
with integrin b5 in COS-7 cells, as examined in a GST pull-down assay. (C) Flag-tagged M
cells. (D) Fusion protein MBP-Myo7a FERM-1 and MBP-Myo7a FERM-2 were incubated w
were used. F1 subdomain of Myo7a FERM-1 domain (E) and F3 subdomain of Myo7a FE
pull-down assay. 10 lg cell lysates were loaded as input.two regions: the N-terminal motor region, including 1–1018 aa
which contains motor domain and neck region, and the C-terminal
tail region, including 1006–2166 aa which contains MyTH4, SH3
and FERM domains (Fig. 1A). GST pull-down experiment showed
that Myo7a tail, but not the N-terminal motor region, could
interact with integrin b5 (Fig. 1D). Furthermore, Co-IP assays were
performed to identify that Myo7a tail interacted with endogenousation of the Myo7a structure and precise amino acid boundaries for each domain of
re transfected into COS-7 cells. Myo7a FERM-1 and FERM-2 domains are associated
yo7a FERM-1 and FERM-2 domains were also interacted with integrin b5 in COS-7
ith GST-integrin b5 in vitro for MBP pull-down assay. Afﬁnity matrices for MBP-tag
RM-2 domain (F) interacted directly with integrin b5 cytoplasmic domain in a GST
Fig. 3. Myo7a regulates integrin avb5-mediated cell spreading and adhesion Western blot assays (A) and Real-time qPCR (B) were performed to detect the efﬁciency of
Myo7a knockdown by twoMyo7a-speciﬁc siRNAs in B16 cells. ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001. (C) Western blot assays show the expression level of Myo7a in Myo7a-transfected MCF-
7 cells. (D) Knockdown of Myo7a promotes cell adhesion on FN and VN. Attachment of Myo7a knockdown B16 cells on collagen type I, FN and VN (6 lg/ml) was analyzed at
30- and 60-min time points as three independent experiments. ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001. (E) The expression level of Myo7a of the above mentioned cells was examined by
Western blot. Data are expressed as mean ± SD of three independent experiments, ⁄⁄P < 0.01. (F) Flag-Myo7a WT or Flag-Myo7a siRNA-2-resistant mutant was transfected
into control or siRNA-2 treated B16 cells. Cell spreading assays showed the different phenotypes of cells with different treatments. Top panel: representative images show
spreading phenotypes of cells on VN (6 lg/ml) at 30-min time points. Scale bar: 50 lm. Lower panel shows quantitative analysis of the above images. ⁄⁄P < 0.01. (G)
Overexpression of Myo7a decreases cell adhesion on VN. Attachment of Myo7a overexpressed MCF-7 cells on type I collagen and VN (6 lg/ml) was analyzed at 30- and 60-
min time points as three independent experiments. ⁄⁄P < 0.01.
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Fig. 4. Myo7a stimulates integrin avb5-mediated cell migration. (A) Knockdown of Myo7a suppresses B16 cell migration in wound healing assay. Left panel shows
representative cell pictures 9 h (⁄P < 0.05; ⁄⁄⁄P < 0.001) and 14 h (⁄⁄P < 0.01; ⁄⁄⁄P < 0.001) after scratching, and right panel shows quantitative analysis of cell migration. (B)
Knockdown of Myo7a inhibits B16 cell migration in a Transwell migration assay. Top panel: crystal violet staining in a Transwell migration assay. Scale bar: 100 lm; bottom
panel: quantitative analysis of cell migration. ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001. (C) The efﬁciency of Myo7a knockdown in B16 cells was examined by Western blot. Data are expressed
as mean ± SD of three independent experiments, ⁄P < 0.05, ⁄⁄P < 0.01. (D) B16 cells co-transfected with Myo7a siRNA-2 and Myo7a siRNA-2 siRNA resistant mutant restored
the ability of cell migration. ⁄⁄P < 0.01. (E) The transfection efﬁciency in the above mentioned cells was determined by Western blot. Data are expressed as mean ± SD of three
independent experiments, ⁄⁄P < 0.01. (F) MCF-7 cells transiently transfected with Flag-tagged Myo7a and empty Flag vector were analyzed for haptotactic cell migration
towards VN in the presence or absence of normal mouse IgG and functional blocking anti-avb5 mAbs. Scale bar: 100 lm. Top panel shows representative images in crystal
violet staining and lower panel shows quantitative analysis of cell migration. ⁄P < 0.05; ⁄⁄P < 0.01.
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between endogenous Myo7a and integrin b5 in B16 cells was found
by Co-IP (Fig. 1F). These results indicated that Myo7a is a novel
integrin-interacting protein through its tail region.
3.2. Integrin b5 subunit interacts with FERM domain of Myo7a tail
To determine the binding regions within Myo7a tail that bind
integrin b5 cytoplasmic domain, we generated ﬁve constructs
encoding various regions of the Myo7a tail as shown in Fig. 2A.
We found that the integrin-binding regions located at the two
FERM domains within Myo7a tail in a GST pull-down assay
(Fig. 2B). Moreover, we constructed Flag-tagged Myo7a FERM
domains and further determined the interaction region between
Myo7a FERM domains and integrin b5 cytoplasmic domain
(Fig. 2C). To rule out the possibility that an adapter protein is med-
iating the interaction between Myo7a tail and the cytoplasmic tail
of integrin b5, we constructed MBP-tagged Myo7a FERM1/2
domains and puriﬁed the MBP–FERM fusion proteins, then incu-
bated the proteins with puriﬁed GST-integrin b5. Results showed
that the tail regions of Myo7a interact directly with integrin b5
cytoplasmic tail (Fig. 2D). Since each FERM domain is composed
of three subdomains, F1, F2 and F3, we further mapped the distinct
subdomains which mediated the interaction in a GST pull-down
assay. Taken together, we identiﬁed that F3 of the ﬁrst FERM
domain and F1 of the second FERM domain interacted with integ-
rin b5 cytoplasmic domain (Fig. 2E and F).
3.3. Myo7a inhibits integrin avb5-mediated cell adhesion
Given the aforementioned ﬁnding that Myo7a interacts with
integrin b5 cytoplasmic domain, we continued to examine the
potential role of Myo7a in avb5-mediated cell adhesion. Two
Myo7a-speciﬁc siRNAs were synthesized and found to signiﬁcantly
inhibit the endogenous Myo7a expression in B16 cells (Fig. 3A and
B). As shown in Fig. 3D, knockdown of Myo7a markedly promoted
cell adhesion on VN, but not integrin b1-mediated cell adhesion on
type I collagen. It was known that both integrin avb3 and avb5
participate in cell attachment and migration towards VN [17],
and integrin avb3 usually serves as VN receptor in most cell lines.
To elucidate the effects of Myo7a on avb5-mediated cell adhesion,
we overexpressed Myo7a in MCF-7 cells (Fig. 3C), which express
avb5 but not avb3 [18]. Intriguingly, we observed that B16 cells
with Myo7a knockdown displayed well-spread morphology with
obvious protrusions on the cell surface compared with control cells
after cell adhesion for 30 min. This effect was speciﬁc as transfec-
tion of a mutant construct, which is resistant to Myo7a siRNA-2
knockdown (Supplementary Fig. 2), notably decreased the percen-
tage of spread cells. Quantitative analysis showed that the
spreading cells accounted for more than 80% of cells with Myo7a
knockdown, whereas less than 25% of spreading cells were
observed after restoring the expression of Myo7a (Fig. 3F). In addi-
tion, ﬁlopodia in Myo7a siRNA2 resistance cells were longer than
the cells with Myo7a knockdown (Supplementary Fig. 3), suggest-
ing that Myo7a was involved in the maintenance of ﬁlopodia.
Fig. 3E showed the expression level of Myo7a of the above
mentioned cells. As expected, overexpression of Myo7a in MCF-7
cells, lacking integrin avb3, inhibited cell adhesion on VN com-
pared with the control group (Fig. 3G). Taken together, these
results indicated that Myo7a inhibited cell spreading and adhesion
in MCF-7 cells is mediated by integrin avb5.
3.4. Myo7a promotes integrin avb5-mediated cell migration
Given that cell adhesion is prerequisite for cell migration, we
attempted to examine whether Myo7a affected cell migration onVN. To test this hypothesis, conﬂuent monolayers of B16 cells
transfected with Myo7a siRNAs and control siRNA were scratched,
and then the cell mobility were observed at different time points
(0 h, 9 h and 14 h). The results demonstrated that knockdown of
Myo7a diminished the velocity of wound healing in B16 cells
(Fig. 4A). Moreover, we performed the Transwell migration assay
to examine the effect of Myo7a on cell migration, and the results
showed that knockdown of Myo7a signiﬁcantly inhibited B16 cell
migration towards VN (Fig. 4B). The efﬁciency of Myo7a
knockdown was examined by Western blot (Fig. 4C). To further
validate the effect of Myo7a on cell migration, B16 cells co-trans-
fected with Myo7a siRNA-2 and Myo7a siRNA-2 resistant mutant
restored the ability of cell migration (Fig. 4D). As shown in
Fig. 4E, the transfection efﬁciency was quantiﬁed by Western blot.
Furthermore, as shown in Fig. 4F, MCF-7 cells were transfected
with Flag-Myo7a or empty Flag vector, and overexpression of
Flag-Myo7amarkedly promoted cell migration towards VN. Impor-
tantly, Flag-Myo7a-induced cell migration could be blocked by a
functional blocking anti-avb5 mAb (Fig. 4F). Collectively, these
data indicated that Myo7a promoted integrin avb5-mediated cell
migration.
4. Discussion
In the present investigation, we delineate previously unknown
integrin-binding capacity for Myo7a and identiﬁed its role in
non-stereocilia cell adhesion and migration. Previous studies have
demonstrated that Myo7a were functionally correlated with
inherited hearing loss. To date, several Myo7a-interacting proteins
have been identiﬁed to play critical roles in maintaining the
structure of stereocilia in the inner ear. The FERM domain of
Myo7a had been identiﬁed to interact with transmembrane
protein vezatin in a yeast two-hybrid screen, which is a ubiquitous
protein of adherens cell–cell junctions [19]. In addition, harmonin,
a PDZ domain-containing protein, interacts directly with Myo7a,
and is absent from the disorganized hair bundles of myosin VIIA
mutant mice [20]. Rzadzinska et al. found that interaction between
Myo7a and twinﬁlin-2 is responsible for the establishment and
maintenance of staircase-like organization of the stereocilia bundle
and that interplay between complexes of Myo7a/twinﬁlin-2 is
responsible for stereocilia length gradation within the bundle stair-
case [21]. In the present report, we identiﬁed a novel interaction
between FERM domain-containing motor molecule Myo7a and
integrin b5 cytoplasmic tail (Fig. 1B). For the ﬁrst time we estab-
lished a new connection between Myo7a and ECM through binding
to integrin. Furthermore, we mapped that the cytoplasmic tail of
integrin b5 binds to F3 subdomain of the ﬁrst FERM domain and
F1 subdomain of the second FERM domain at the C-terminus of
Myo7a (Fig. 2D and E). Interestingly, Rzadzinska et al. pointed
out that exogenous expression of Myo7a in BHK-21 ﬁbroblast cells
results in a reduced number of ﬁlopodia, the amount of Myo7a in
the cell cytoplasm correlates with the number of actin ﬁlled cellu-
lar protrusion and higher levels of Myo7a in the cell cytoplasm
strongly correlate with ﬁlopodia suppression [21]. These ﬁndings
suggested that overexpressed cytoplasmic Myo7a interact with
integrins, e.g., avb5 and connects with the ECM. Thus, more Myo7a
are not favorable for the formation of ﬁlopodia, resulting in less
ﬁlopodia in number and shorter ﬁlopodia in length. In our work,
we identiﬁed that Myo7a regulates cell adhesion and migration
through integrin avb5. We found that knockdown of endogenous
Myo7a in B16 cells by RNAi promotes cell spreading, adhesion
and inducing protrusions at the peripheral of cells (Fig. 3F and
Supplementary Fig. 2), suggesting that knockdown of Myo7a may
facilitate the initiation of ﬁlopodia since reduced cell-matrix
contact favors the formation of protrusion at this stage. However,
our data also demonstrated that ﬁlopodia in cells expressing
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cells with Myo7a knockdown (Supplementary Fig. 3), suggesting
that Myo7a is involved in the maintenance of the length of ﬁlopo-
dia, probably by formation of tip complexes with integrin avb5 or
twinﬁlin-2. Therefore, if Myo7a could complex with integrin avb5
and twinﬁlin-2 at the tips of stereocilia to regulate the length
gradation warrants future investigations.
We previously found that p21-activated kinase 4 (PAK4) inter-
acts with the integrin b5 cytoplasmic domain and regulates
avb5-mediated breast cancer cell migration [14]. These ﬁndings
suggested that integrin avb5 plays an important role in the regula-
tion of cell migration. Integrin b5 has been reported to contribute
to the tumorigenesis of breast cancer cells [22]; meanwhile recent
study showed that Myo10 was required for breast cancer cell inva-
sion and dissemination by association with mutant p53 [23]. These
related ﬁndings raised an important question that whether Myo7a
plays a role in tumor progression via interaction with integrin b5.
However, evidence for the role of Myo7a in tumor progression
remains elusive.
In summary, we identiﬁed that Myo7a is a novel integrin
b5-interacting protein. By interaction with integrin, we pointed
out that Myo7a is linked to the ECM. Myo7a plays a role in regulat-
ing integrin avb5-mediated cell adhesion and migration in non-
stereocilia cells, a ﬁnding that expanded our current knowledge
on Myo7a. The identiﬁcation of Myo7a-integrin b5 interaction
may shed light on the deeper understanding of the role of Myo7a
in the progression of hereditary deafness and maintenance of the
structural integrity of stereocilia in the inner ear.
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